Short Interest in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Drops By 0.6%

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 1,568,110 shares, a drop of 0.6% from the February 28th total of 1,577,132 shares. Based on an average trading volume of 101,913 shares, the short-interest ratio is presently 15.4 days. Currently, 4.0% of the company’s shares are short sold.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc increased its stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 6.1% during the 3rd quarter. Vanguard Group Inc now owns 145,747 shares of the company’s stock worth $273,000 after buying an additional 8,381 shares in the last quarter. Geode Capital Management LLC grew its position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 13.3% in the fourth quarter. Geode Capital Management LLC now owns 136,655 shares of the company’s stock worth $168,000 after acquiring an additional 16,065 shares during the period. Rhumbline Advisers grew its position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 56.5% in the fourth quarter. Rhumbline Advisers now owns 46,410 shares of the company’s stock worth $57,000 after acquiring an additional 16,750 shares during the period. BlackRock Inc. grew its position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 2.3% in the fourth quarter. BlackRock Inc. now owns 1,767,342 shares of the company’s stock worth $2,173,000 after acquiring an additional 40,244 shares during the period. Finally, Northern Trust Corp purchased a new position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the second quarter worth approximately $144,000. 14.59% of the stock is owned by institutional investors.

Shares of ZOM stock traded up $0.03 on Friday, reaching $0.34. 237,178 shares of the company’s stock were exchanged, compared to its average volume of 143,101. Zomedica Pharmaceuticals Corp has a 52 week low of $0.28 and a 52 week high of $2.98. The firm has a market capitalization of $34.57 million, a P/E ratio of -1.89 and a beta of 0.11.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last issued its quarterly earnings data on Tuesday, February 26th. The company reported ($0.09) earnings per share (EPS) for the quarter.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/zomedica-pharmaceuticals-corp-nyseamerican-zom-sees-large-decrease-in-short-interest.html.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Recommended Story: Fundamental Analysis and Individual Investors

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.